Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin(R) for Multiple Sclerosis

Posted Jan 14 2009 8:24pm
Press Release Source: Opexa Therapeutics, Inc.
Yahoo Finance

Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin(R) for Multiple Sclerosis -
Tuesday July 22, 8:00 am ET


THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc., a company leading in the development of cell therapies for multiple sclerosis (MS) and diabetes, has completed an internal assessment of data from its Phase I/II two year extension study with Tovaxin in patients with MS. While confirming the favorable safety and efficacy profile of Tovaxin, further analysis also confirms both the benefit of consecutive annual treatments with Tovaxin and the advantage of tailoring each vaccination to the patient’s changing disease profile.

» Read More

===========================================

If you want to leave a comment to this article, you need to return-to
(or remain on) - this page

============================================
Post a comment
Write a comment:

Related Searches